恶性胶质瘤术后应用替莫唑胺化疗联合放疗的临床观察

Clinical Observation in Temozolomide Combined with Radiotherapy in Treatment of Postoperative Malignant Glioma

摘要: 目的比较替莫唑胺联合放疗和单纯放疗对恶性胶质瘤术后治疗的疗效和安全性。方法选择2002~2003年收治的38例术后病理证实为恶性胶质瘤的病人,随机分为2组。实验组(22例)在放疗的同时采用替莫唑胺化疗,随后进行6个周期的化疗;对照组(16例)仅行放疗。长期随访,观察病人的无进展生存时间和总的生存时间以及药物的安全性。结果实验组的平均无进展生存时间为(10.97±6.14)月,对照组为(6.20±3.68)个月(P<0.05)。实验组总的生存时间为(14.89±10.08)个月,对照组为(8.26±4.80)个月(P<0.05)。常见的副作用为恶心、呕吐和乏力等,仅有两个病人表现为白细胞减少,经过对症处理和药物减量后病情好转。结论替莫唑胺和放疗联合治疗胶质瘤的效果要好于单纯放疗,病人可以较好的耐受联合治疗。

Abstract: Objective To compare the efficiency and safety of temozolomide administered concomitantly and adjuvantly to radiotherapy versus radiotherapy alone in patients with postoperative malignant glioma. Methods 38 postoperative patients with pathologically confirmed malignant glioma were randomly assigned to receive temozolomide 75mg/m² /d orally,concomitantly with radiotherapy (experiment group; n=22),followed by six cycles of temozolomide (150mg/m² /d orally),or radiotherapy alone (control group; n=16).The pa...